PROGRAM DESCRIPTION CARDIOVASCULAR FELLOWSHIP HARTFORD ...Document Transcript
HARTFORD HOSPITAL/UNIVERSITY OF CONNECTICUT
Program Director: Gary V. Heller, MD, Ph.D. Associate Directors: Donna M. Polk, MD, MPH
Justin B. Lundbye, MD
80 Seymour Street, P.O. Box 5037
Hartford, CT 06102-5037
Fellowship Coordinator: Betty Doucette
Director, Cardiology: Paul D. Thompson, MD
Associate Directors, Cardiology: Gary V. Heller, MD, Ph.D.
Jeffrey Kluger, MD
Full-Time Faculty: Paul D. Thompson, MD Gary V. Heller, MD, Ph.D.
Christopher Clyne, MD Jeffrey Kluger, MD
Francis J. Kiernan, MD Justin B. Lundbye, MD
Donna M. Polk, MD Joseph Radojevic, M.D.
Detlef Wencker, MD David I. Silverman, MD
Steven Zweibel, MD
Francis J. Kiernan, MD, Director Jeffrey Hirst, MD
Charles A. Primiano, MD Daniel Fram, MD
Raymond G. McKay, MD Joseph Mitchel, DO
David I. Silverman, MD
Heart Rhythm Management & Interventional Electrophysiology
Jeffrey Kluger, MD, Director Christopher Clyne, MD, Director, Interventional
Steven Zweibel, MD, Director, Electrophysiology
Nuclear Cardiology Exercise Laboratory
Gary V. Heller, MD, Ph.D., Director Charles A. Primiano, MD, Director
Preventive Cardiology Coronary Intensive Care Unit
Donna M. Polk, MD, MPH, Director Justin B. Lundbye, MD, Director
Ellen Dornelas, Ph.D.
Heart Failure Services
Detlef Wencker, MD, Director
Joseph Radojevic, M.D.
Current Cardiovascular Fellows
First Year Residency
Srilatha Ayirala, MBBS Michigan State University
Talhat Azemi, MD University of Connecticut
Aravind Kokkirala, MBBS St. Luke’s-Roosevelt Hospital
Raja Pullatt, MBBS University of Connecticut
Steven Borer, DO University of Connecticut
A. Farooq Iqtidar, MD Dartmouth-Hitchcock Medical Ctr
Fawad A. Kazi, MD University of Connecticut
Anuj R. Shah, MD University of Connecticut
Peter Chien, MD Georgetown
Amyn Malik, MD University of Minnesota
Yaqoob A. Mohyuddin, MD University of Virginia
Kyle Richards, MD University of Connecticut
Arshad M. Yekta, MD Mt. Sinai Hospital, NY
Non-Invasive Cardiology Fellows
Osman Faheem, MBBS University of Connecticut
Anupama Voodarla, MBBS Brooklyn Hospital
James Cardon, MD Anthony LaSala, MD
David M. Casey, MD Reza Mansoor, MD
James Dougherty, MD Bekir Melek, MD
Brett Duncan, MD Kenneth Merkatz, MD
Andrew Feingold, MD Dariush Owlia, MD
Melissa Ferraro-Borgida, MD Lawrence Pareles, MD
Carol Gemayel, MD Ronald Pariser, MD
Steve Goldblatt, MD Asad Rizvi, MD
John Granquist, MD Fred Rubin, MD
Steve Horowitz, MD Donald Ruffett, MD
James Kallal, MD Kevin Tally, MD
Stephen Kastoff, MD Jeffrey Walden, MD
The Cardiovascular Disease Program at Hartford Hospital/University of Connecticut is a three-year program
specifically designed to prepare cardiovascular fellows for the practice of Cardiology. While in the three-year
program, fellows receive training in basic cardiovascular diseases, clinical cardiology, and subspecialty
practices. This is accomplished in several ways including clinical rotations which allows exposure to
cardiovascular related diseases and problems, didactic sessions covering basic mechanisms of cardiovascular
diseases, dedicated research months and subspecialty rotations. During the clinical rotations, the
cardiovascular disease fellow interviews, examines and formulates basic evaluations in patients with
cardiovascular related illnesses. During subspecialty training, cardiovascular disease fellows are exposed to
the practices of cardiac catheterization, preventive cardiology, arrhythmias, nuclear cardiology,
echocardiography, cardiovascular surgery, pacemaker techniques and interventional electrophysiology.
During the third year, the cardiovascular disease fellow chooses either an invasive or non-invasive track for
additional training in one of those areas. At the completion of the cardiovascular disease program, the fellow is
qualified to enter the practice of cardiovascular diseases either in the invasive, non-invasive or clinical areas.
Although, not specifically part of the cardiovascular disease program, interested fellows may choose a fourth
year subspecializing in various aspects of cardiology in hopes of pursuing an academic career. The
Interventional Cardiology Program at Hartford Hospital is ACGME approved and is an option for further
The research experience in the cardiovascular disease program is designed to allow the fellow ample
exposure to the process of designing, performing data analysis, and manuscript preparation of a research
project. Research is begun in the first year specifically to allow the cardiovascular disease fellow opportunity
to gain skill and knowledge in the performance of cardiovascular disease research and to allow time for
completion of study. The early exposure to research also allows the fellow the opportunity to evaluate the
possibility of entering academic cardiology. Fellows engaged in research are expected to prepare results for
abstract and manuscript submission. Local hospital funding is available for support of projects, and several
attending physicians have national support for studies. Dr. Paul D. Thompson is supervisor of the research
experience for the fellows.
Fellowship Length and Rotations
The University of Connecticut/Hartford Hospital Cardiovascular Disease Fellowship Program consists of a 3-
year blend of Clinical Cardiology, subspecialty training, and research. Hartford Hospital is one of the largest
cardiovascular volume hospitals in the New England area and exposes the fellows to a wide range of cases,
which will be encountered in future cardiovascular practice.
The 1st year is primarily clinical and includes the consultation service, coronary care unit, and subspecialties of
arrhythmia, echocardiography, nuclear cardiology, cardiac catheterization, and preventive cardiology. One
month is set aside for research. The duties of the fellows are to gain knowledge in the various subspecialties
and how they interact with clinical cardiology. Early exposure to subspecialties that separates the cardiology
fellow from their internal medicine background is a key component of the program prior to CICU and
The 2nd year is a similar format to the 1st year rotations with the exception of 2 months of research and
elective time. In the 2nd year the fellow has more in depth exposure to clinical cardiovascular medicine as well
as each of the subspecialties, and assumes greater responsibilities.
The 3rd year fellow can choose two pathways between invasive and non-invasive cardiology. If the fellow
chooses the invasive pathway, 9 months are spent in the cardiac catheterization laboratory and 3 months in
research. A non-invasive pathway includes rotations in nuclear cardiology, echocardiography, and 3 months of
research, which can be tailored to the individual fellow needs.
The fellows attend daily conferences, which include non-invasive cardiology, cardiac catheterization,
arrhythmia/ECG, journal club, cardiology grand rounds, lipid management, research combined surgical/cardiac
rounds and chief’s rounds. . For each lecture series, presentations include basic descriptions of the
subspecialty as well as clinical discussions. Cardiology grand rounds consists of nationally recognized
speakers discussing all relevant topics in cardiology. Once a month the fellows have the opportunity to meet
with and present cases to an outside expert. In addition, the fellows undergo a 2-month course in
cardiovascular diseases in July and August of each year. This course is designed to acquaint the incoming
fellows with acute situations they may encounter as well as topics that may not be covered in other venues.
Clinical Cardiology Service: The Clinical Cardiology Service consists of both the Coronary Intensive Care
Unit (CICU) and the Consultation Service. The concept is to provide a strong basis of clinical training for the
Cardiac Intensive Care Unit Rotation: The primary responsibility of the cardiology fellow during a CICU
rotation is to train and supervise medical students, interns and residents while overseeing the care of the
patients in the CICU. Approximately 90-95% of patient admissions to the Cardiac Intensive Care Unit are done
by private attending cardiologists. The remainder of patients are admitted to the Cardiology Fellow Service.
The cardiology fellow, therefore, cares directly only for the fellow service patients and indirectly for the private
cardiology patients by directing the care with house staff. In addition, the fellow helps to insert and
troubleshoot Swan Ganz catheters as well as intra-aortic balloon pumps. Lastly, the cardiology fellow is
responsible for all cardiac emergencies in the hospital during the CICU rotation, including being the code
champion at cardiac alerts.
Consultation Service: The Consultation Service at Hartford Hospital is responsible for all requests for
cardiology consultations by in-hospital services. These services include internal medicine, surgery,
obstetrics/gynecology, neurosurgery, etc. These consultations include such topics as preoperative evaluation,
cardiac contusion, management of acute coronary syndromes, and congestive heart failure. The Cardiology
Fellow in conjunction with the service attending evaluates all patients, performs physical examinations, and
develops a diagnostic and management strategy. The attending physician with the Cardiology Fellow sees
and evaluates all patients who undergoes cardiac consultation. In addition, the Cardiology Fellow is
responsible the Chief’s Cardiology Service. These are admitted patients who have no assigned physician.
Patients admitted to the Chief’s service carry such diagnoses as acute coronary syndrome, congestive heart
failure, bacterial endocarditis, and other cardiovascular related illnesses.
Outpatient Cardiovascular Clinic: An important part of the cardiovascular fellowship is the Outpatient
Cardiovascular Clinic. Sessions are held Thursday and Friday afternoons on a weekly basis. Cardiovascular
Fellows are assigned to one of these times and continue that time throughout the year. Unassigned patients
who choose to receive services at the Brownstone Clinic are seen by Cardiology Fellows. These include
patients with chronic stable angina, multiple valvular disorders, congestive heart failure, and arrhythmias. An
attending physician is assigned to the clinic. The attending physician examines, and develops management
strategies with the Cardiovascular Fellow. In addition to the unassigned patient, any recently hospitalized
patient is followed in the Cardiovascular Clinic. Patients are also referred from the Internal Medicine Clinics
seen in the same building.
After an initial evaluation, the patients seen by the Cardiology Fellow may be followed for the duration of the
Cardiovascular Fellow’s tenure. It is expected that the Cardiology Fellow will follow any patients from the
Cardiovascular Clinic who are hospitalized. The fellow in conjunction with the Consultation/CICU fellow will
assist in diagnostic and management decisions.
The Outpatient Cardiovascular Clinic is a rich and rewarding part of the Cardiovascular Fellowship. This
experience gives the Fellows long-term longitudinal exposure to further refine management strategies over
time. Hartford Hospital is a primary and tertiary care center with referrals from the northern Connecticut area.
Heart Rhythm Management/Interventional Electrophysiology Service: Heart Rhythm Management
Services at Hartford Hospital consist of a diagnostic and interventional electrophysiology laboratories, Syncope
Center, one of the largest device clinics in the region (8,000 encounters/year) and a busy consultation service.
During the first year the fellow performs consultations in conjunction with the attending physician and assists in
various studies such as electrophysiologic testing, tilt-table testing, holter monitoring and arrhythmia
recognition. Fellows attend pacemaker and ICD clinics and learn device interrogation and programming.
The heart rhythm management service is a busy one with over 1,000 consultations annually. EP studies and
tilt-table tests are performed on a daily basis. Catheter ablation and biventricular pacing procedures are on the
cutting edge of interventional electrophysiology. The goals of the first year are to become skilled at
identification and treatment of arrhythmias, understand the role of electrophysiology and tilt studies and to
perform device interrogation.
The 2nd year fellow performs at least one month and possibly two months of advanced training and is expected
to be more skilled in the evaluation of patients with arrhythmias as well as the performance of related
procedures such as tilt-table testing, EPS, and assisting in catheter ablations.
Cardiac Catheterization: Hartford Hospital has an active catheterization program. The facility consists of
four adult cardiac catheterization suites equipped with digital x-ray systems. On an annual basis
approximately 3700 procedures are performed including 1200 coronary interventional procedures. The
patients who are referred to the laboratory represent a broad spectrum of cardiac pathology. The procedures
offered include diagnostic cardiac catheterization, balloon angioplasty, coronary stent placement and the use
of new and investigational devices. The vast majority of patients who present to Hartford Hospital with acute
myocardial infarction are referred to the laboratory for primary intervention. The teaching faculty consists of
seven cardiologists who are geographically based in the laboratory.
Fellows in the first and second year of training are exposed to diagnostic right and left heart catheterization
including coronary angiography. They participate in the pre-procedure evaluation of the patient and participate
with the attending in the performance of the procedure and interpretation of results. The major emphasis in the
first two years is acquiring knowledge of basic coronary anatomy and hemodynamics. Fellows in their third
year can elect to spend nine months in the laboratory in order to obtain in-depth training in cardiac
catheterization. Hartford Hospital also offers a dedicated fourth year of training in interventional cardiology, an
ACGME approved program.
In addition to clinical activities and teaching, the fellows have an opportunity to participate in the research
activities of the laboratory. There is an active patient database that can be used for clinical research. The
laboratory is involved with testing of new devices as part of clinical trials. There is also an animal facility for
basic research. These activities have resulted in a number of presentations and publications by cardiology
Echocardiography Laboratory: The Echocardiography Laboratory performs over 7,000 studies annually.
Equipment includes state of the art Siemens and Phillips systems with emergency imaging performed 24 hours
a day. The Echocardiography section provides comprehensive didactic and clinical training in the performance
and interpretation of Echocardiograms. Training includes hands-on acquisition of transthoracic images with
digital and tape storage and retrieval technology. The basics of ultrasound and Doppler physics are taught at
length in didactic sessions. The fellow will become adept at performance and interpretation of complete
transthoracic echocardiograms. Tools such as M-mode, second harmonic imaging, contrast echocardiography
and power Doppler will be used on routine clinical examinations to enhance the diagnostic information
obtained from the test. The first year fellow will spend 2 months in Echocardiography and will be expected to
perform transthoracic echocardiograms on call with the assistance and backup of a Cardiac Sonographer and
Attending. Research participation is encouraged. The objective of the first year in Echocardiography is to
become adept at the utilization of echocardiography in clinical practice as a diagnostic tool.
The second year fellow will continue with regularly scheduled didactic sessions reviewing the basic principles
of Echocardiography. The fellow will continue to advance manual skills in the independent performance of
transthoracic echocardiograms. The fellow will also be asked to regularly interpret complete transthoracic
echocardiograms with a focus on providing a clinical diagnosis and a thorough interrogation of associated
cardiac abnormalities. The objective of the second year in Echocardiography is to become adept at the
independent performance and interpretation of complete transthoracic echocardiographic studies.
The objective of the third year noninvasive Echocardiography program is to add procedural skills. The fellow
will be trained in the performance of transesophageal and stress echocardiography (exercise treadmill and
dobutamine stress). The fellow will continue active involvement in the didactic sessions and clinical
performance and interpretation of transthoracic echocardiograms. The fellow who chooses the noninvasive
path will spend 3-6 months in Echocardiography. A supplemental program is available for those who wish to
sit for the ASE examination in Echocardiography.
Nuclear Cardiology: The Nuclear Cardiology Laboratory is an integral part of the Cardiology Division and
performs over 3,500 nuclear cardiology procedures annually. Equipment includes 3 dual head cameras on site
and 3 satellite office locations as well as stress testing with oxygen consumption equipment. The Nuclear
Cardiology Laboratory is part of the Cardiology Division and directed by a board certified nuclear cardiologist.
Procedures include a myocardial perfusion imaging associated with gated-SPECT imaging, radionuclide
ventriculography, shunt studies, myocardial infarct avid imaging as well as several experimental procedures
with new radiopharmaceuticals in the development stages. The pharmacologic stress testing includes
vasodilator stress with both dipyridamole and adenosine as well as inotropic stress with dobutamine.
Cardiology fellows in the first and second year of training are exposed to four months of dedicated nuclear
cardiology which afford them ample opportunity to perform exercise and pharmacology stress testing, and
interpret nuclear cardiology procedures with an attending physician. The indications for the procedure as well
as clinical implications of findings are discussed. A Non-Invasive conference shared by Echocardiography is
held weekly. During the second year the fellow is expected to spend time with technologists to gain an
understanding of image acquisition processing and quality control. Time is spent learning technical problems
that can occur during the acquisition and processing of nuclear procedures. Fellows in the third year who opt
to seek certification in nuclear cardiology may enroll in the University of Connecticut Nuclear Medicine Division
Radiation Physics Course to gain certification of the 200 didactic hours required by the Nuclear Regulatory
Commission. The third year fellow may gain enough participation for either Level 2 or Level 3 by ACC
guidelines. The Level 3 accreditation requires one full year of participation in nuclear cardiology and allows the
fellow to fully operate a nuclear cardiology laboratory. An optional fourth year of dedicated research is also
Preventive Cardiology: The Preventive Cardiology experience is integrated into the fellowship program with
the concept that all well-trained cardiologists should know the principles of primary and secondary heart
disease prevention. Preventive Cardiology includes the Cholesterol Management Center, the Nicotine
Treatment Center, the Cardiac Rehabilitation Program, and the Exercise Research Program. First year fellows
spend a one-month rotation in Preventive Cardiology. The fellow spends time in the Cholesterol Management
Center addressing difficult lipid cases, attends smoking cessation clinic, and assists with Cardiac
Rehabilitation. There are also didactic sessions provided to all fellows monthly to discuss preventive
strategies. By the completion of the fellowship program, the fellow will know advanced lipid physiology, how
the lipid lowering agents work, how to counsel patients in smoking cessation, the principles of exercise
physiology and how they apply to active patients, and basic hypertension management.
Research: The ACGME requires a minimum of 6 months research during the cardiovascular fellowship
program. Each fellow is therefore expected to participate in active research projects during his/her fellowship
period. Ample opportunity is provided for such experience beginning in the first year. Each year the fellow is
expected to become more independent in his/her research but always with the guidance of a mentor. The
research fellow is at liberty to choose any attending physician they wish for such guidance. The research
environment at Hartford Hospital is extremely strong with participation in both independent and multi-center
research projects. The fellows are encouraged to participate in independent research during the fellowship
years. Funding is available if necessary through the Research Administration at Hartford Hospital. During the
second and third years, if research has progressed, the fellow is encouraged to submit abstracts for the
American Heart Association and American College of Cardiology meetings in addition subspecialty meeting
applications are also possible. If accepted the fellow is expected to prepare the abstracts for presentation and
move towards manuscript preparation. Recent publications by the Division of Cardiology are provided to
demonstrate the productivity of the Division.
The fellows’ progress is reviewed by a Residency Committee, which meets twice a year. In addition, the
Program Director meets every 3 months with the fellow to discuss their evaluations by the attendings. The
fellows’ research progress is also discussed during this time. The Program Director meets monthly with all
fellows to discuss new information, problems and successes of the cardiovascular disease program.
R e c e n t P u b l i c a t i o n s b y t h e
C a r d i o l o g y D i v i s i o n
Thompson PD, Tsongalis G, Ordovas JM, Seip RL, Bilbie C, Miles M, Zoeller R, Visich P, Gordon
P, Angelopoulos TJ, Pescatello L, Moyna N. Angiotensin-Converting Enzyme Genotype and
Adherence to Aerobic Exercise Training. Preventive Cardiology, 9:21-4, 2006.
Ouyang P, Tardif JC, Herrington DM, Stewart KJ, Thompson PD, Walsh MN, Bennett SK,
Heldman AW, Tayback MA, Wang NY; for the Estrogen And Graft Atherosclerosis Research
(EAGAR) investigators. Randomized trial of hormone therapy in women after coronary bypass
surgery Evidence of differential effect of hormone therapy on angiographic progression of disease
in saphenous vein grafts and native coronary arteries. Atherosclerosis. 189:375-86, 2006.
Ruano G, Seip RL, Windemuth A, Zollner S, Tsongalis GJ, Ordovas J, Otvos J, Bilbie C, Miles M,
Zoeller R, Visich P, Gordon P, Angelopoulos TJ, Pescatello L, Moyna N, Thompson
PD.Apolipoprotein A1 genotype affects the change in high density lipoprotein cholesterol
subfractions with exercise training. Atherosclerosis. 185:65-9, 2006.
Blanchard BE, Tsongalis GJ, Guidry MA, LaBelle LA, Poulin M, Taylor AL, Maresh CM, Devaney J,
Thompson PD, Pescatello LS. AAS polymorphisms alter the acute blood pressure response to
aerobic exercise among men with hypertension. Eur J Appl Physiol. 97:26-33, 2006.
Clarkson PM, Kearns AK, Rouzier P, Rubin R, Thompson PD. Serum creatine kinase levels and
renal function measures in exertional muscle damage. Med Sci Sports Exerc. 38:623-7, 2006.
Cosio-Lima LM, Thompson PD, Reynolds KL, Headley SA, Winter CR, Manos T, Lagasse MA,
Todorovich JR, Germain M. The acute effect of aerobic exercise on brachial artery endothelial
function in renal transplant recipients. Prev Cardiol. 9:211-4, 2006.
Syme AN, Blanchard BE, Guidry MA, Taylor AW, Vanheest JL, Hasson S, Thompson PD,
Pescatello LS. Peak systolic blood pressure on a graded maximal exercise test and the blood
pressure response to an acute bout of submaximal exercise. Am J Cardiol. 98:938-43, 2006.
Seip RL, Otvos J, Bilbie C, Tsongalis GJ, Miles M, Zoeller R, Visich P, Gordon P, Angelopoulos TJ,
Pescatello L, Moyna N, Thompson PD. The effect of apolipoprotein E genotype on serum
lipoprotein particle response to exercise. Atherosclerosis. 188:126-33, 2006.
Guidry MA, Blanchard BE, Thompson PD, Maresh CM, Seip RL, Taylor AL, Pescatello LS. The
influence of short and long duration on the blood pressure response to an acute bout of dynamic
exercise. Am Heart J. 151:1322.e5-12, 2006.
Pescatello LS, Kostek MA, Gordish-Dressman H, Thompson PD, Seip RL, Price TB, Angelopoulos
TJ, Clarkson PM, Gordon PM, Moyna NM, Visich PS, Zoeller RF, Devaney JM, Hoffman EP. ACE ID
genotype and the muscle strength and size response to unilateral resistance training. Med Sci
Sports Exerc. 38:1074-81, 2006.
Urso ML, Scrimgeour AG, Chen YW, Thompson PD, Clarkson PM. Analysis of human skeletal
muscle after 48 h immobilization reveals alterations in mRNA and protein for extracellular matrix
components. J Appl Physiol. 101:1136-48, 2006.
Patel MD, Thompson PD. Phytosterols and vascular disease.Atherosclerosis. 186:12-9, 2006.
Thompsen J, Thompson PD. A systematic review of LDL apheresis in the treatment of
cardiovascular disease. Atherosclerosis. Mar 16, 2006.
Thompson PD, Clarkson PM, Rosenson RS; The National Lipid Association Statin Safety Task
Force Muscle Safety Expert Panel. An assessment of statin safety by muscle experts. Am J
Cardiol. 97:69C-76C, 2006.
Roberts BH, Thompson PD. Is there evidence for the evidence-based guidelines for
cardiovascular disease prevention in women? Gend Med. 3:5-12, 2006.
Pelliccia A, Thompson PD. The genetics of left ventricular remodeling in competitive
athletes. J Cardiovasc Med (Hagerstown). 7:267-70, 2006.
Kapetanopoulos A, Kluger J, Maron BJ, Thompson PD. The congenital long QT syndrome
and implications for young athletes. Med Sci Sports Exerc. 38:816-25, 2006.
Baghdasarian SB, Thompson PD. How safe are very low LDL cholesterol levels? Nat Clin
Pract Cardiovasc Med. 3:306-7, 2006.
Ruffin R, Thompson PD. Can exercise prevent the common cold? Am J Med. 119:909, 2006.
Fernandez A, Sorokin A, Thompson PD. Corneal arcus as coronary artery disease risk factor.
Atherosclerosis. Oct 16, 2006.
Thompson PD, Levine BD. Protecting athletes from sudden cardiac death. JAMA. 296:1648-
Williams PT, Thompson PD. Dose-dependent effects of training and detraining on weight in
6406 runners during 7.4 years. Obesity (Silver Spring). 2006 Nov;14(11):1975-84.
Pescatello LS, Turner D, Rodriguez N, Blanchard BE, Tsongalis GJ, Maresh CM, Duffy V,
Thompson PD. Dietary calcium intake and Renin Angiotensin System polymorphisms alter the
blood pressure response to aerobic exercise: a randomized control design. Nutr Metab (Lond).
2007 Jan 4;4:1.
Pistilli EE, Gordish-Dressman H, Seip RL, Devaney JM, Thompson PD, Price TB, Angelopoulos TJ,
Clarkson PM, Moyna NM, Pescatello LS, Visich PS, Zoeller RF, Hoffman EP, Gordon PM. Resistin
polymorphisms are associated with muscle, bone, and fat phenotypes in white men and women.
Obesity (Silver Spring). 2007 Feb;15(2):392-402.
Dornelas EA, Stepnowski RR, Fischer EH, Thompson PD. Urban ethnic minority women's
attendance at health clinic vs. church based exercise programs. J Cross Cult Gerontol. 2007
Mar;22(1):129-36. Epub 2006 Nov 28.
Thompson PD, Apple FS, Wu A. Marathoner's heart? Circulation. 2006 Nov
Sorokin A, Brown JL, Thompson PD. Primary biliary cirrhosis, hyperlipidemia, and
atherosclerotic risk: A systematic review. Atherosclerosis. 2007 Jan 19; [Epub ahead of print]
John S, Sorokin AV, Thompson PD. Phytosterols and vascular disease. Curr Opin Lipidol. 2007
Maron BJ, Thompson PD, Ackerman MJ, Balady G, Berger S, Cohen D, Dimeff R, Douglas PS,
Glover DW, Hutter AM Jr, Krauss MD, Maron MS, Mitten MJ, Roberts WO, Puffer JC; American
Heart Association Council on Nutrition, Physical Activity, and Metabolism. Recommendations
and considerations related to preparticipation screening for cardiovascular abnormalities in
competitive athletes: 2007 update: a scientific statement from the American Heart Association
Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of
Cardiology Foundation. Circulation. 2007 Mar 27;115(12):1643-455. Epub 2007 Mar 12.
Dornelas EA, Thompson PD. Smoking cessation for cardiac patients. Prev Cardiol. 2007
Spring;10(2 Suppl 2):31-3.
Haskell WL, Lee IM, Pate RR, Powell KE, Blair SN, Franklin BA, Macera CA, Heath GW, Thompson PD,
Bauman A. Physical Activity and Public Health. Updated Recommendation for Adults From the
American College of Sports Medicine and the American Heart Association. Circulation, Aug 2007.
Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic
review. J Am Coll Cardiol. 49:2231-7, 2007.
Thompson PD, Franklin BA, Balady GJ, Blair SN, Corrado D, Estes NA 3rd, Fulton JE, Gordon NF,
Haskell WL, Link MS, Maron BJ, Mittleman MA, Pelliccia A, Wenger NK, Willich SN, Costa F; American
Heart Association Council on Nutrition, Physical Activity, and Metabolism; American Heart Association
Council on Clinical Cardiology; American College of Sports Medicine. Exercise and acute cardiovascular
events placing the risks into perspective: a scientific statement from the American Heart Association
Council on Nutrition, Physical Activity, and Metabolism and the Council on Clinical Cardiology.
Circulation. 115:2358-68, 2007.
Thompson PD. Cardiovascular adaptations to marathon running : the marathoner's heart. Sports Med.
Gadarla MR, Pullatt RC, Thompson PD. Role of Cardiac Rehabilitation after Acute Coronary Syndromes.
Acute Coronary Syndromes. 8:49-55, 2007.
Haskell WL, Lee IM, Pate RR, Powell KE, Blair SN, Franklin BA, Macera CA, Heath GW,
Thompson PD, Bauman A. Physical activity and public health: updated recommendation for
adults from the American College of Sports Medicine and the American Heart Association. Med
Sci Sports Exerc. 39:1423-34, 2007.
Baggish AL, Thompson PD. The Athlete's Heart 2007: Diseases of the Coronary Circulation.
Cardiol Clin. 25:431-40, 2007.
Sewright KA, Clarkson PM, Thompson PD. Statin myopathy: incidence, risk factors, and
pathophysiology. Curr Atheroscler Rep. 9:389-96, 2007.
Thompson PD, Estes III NAM. The Athlete’s Heart. In textbook of Cariovascular Medicine 3rd
Edition ed. EJ Topol. Lippincott-Raven 686-697889-901, 2007.
Bateman T, Heller GV, McGhie I, Friedman J, Case J, Bryngelson J, Hertenstein G, Moutray K,
Reid K, Cullom SJ. Diagnostic Accuracy of Rest/Stress ECG-gated Rubidium-82 Myocardial
Perfusion PET: Comparison with ECG-gated Tc-99m-Sestamibi SPECT. J Nucl Cardiol
Papaioannou GI, Kasapis, C, Seip RL, Grey NJ, Katten D, Wackers FJ, Inzucchi SE, Engel S, Taylor
A, Young LH, Chyun DA, Davey JA, Iskandrian AE, Ratner RE, Robinson EC, Carolan S, Heller
GV. Value of peripheral vascular endothelial function in the detection of relative myocardial
ischemia in asymptomatic type 2 diabetic patients who underwent myocardial perfusion imaging.
J Nucl Cardiol 2006;13:362-8.
Chyun DA, Melkus GD, Katten DM, Price WJ, Davey JA, Grey N, Heller GV, Wackers FJTh. The
Association of Psychological Factors, Physical Activity, Neuropathy, and Quality of Life in Type 2
Diabetes. Biological Research for Nursing 2006, 7 (4):279-288.
Shaw LJ, Heller GV, Casperson P, Miranda-Peats R, Slomka P, Friedman J, Hayes SW, Schwartz
R, Weintraub WS, Maron DJ, Dada M, King S, Teo K, Hartigan P, Boden WE, O’Rourke RA,
Berman DS. Gated myocardial perfusion single photon emission computed tomography in the
clinical outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) trial,
Veterans Administration Cooperative study no. 424. J Nucl Cardiol 2006;13:685-98.
Singh, B, Bateman TM, Case JA, Heller GV. Attenuation artifact, attenuation correction, and the
future of myocardial perfusion SPECT. J Nucl Cardiol 2007;14:153-64.
Kapetanopoulos A, Ahlberg, AW, Taub C C, Katten DM, Heller GV. Regional Wall Motion
Abnormalities on Post-Stress Electrocardiographic-Gated Tc-99mSestamibi Single-Photon Emission
Computed Tomography Imaging Predict Cardiac Events. J Nucl Cardiol 2007;14:810-7.
Wackers F J Th, Chyun DA, Young LH, Heller GV, Iskandrian AE, Davey JA, Barrett EJ, Taillefer
R, Wittlin SD, Filipchuk N, Ratner RE, Inzucchi SE. Resolution of Asymptomatic Myocardial
Ischemia in Patients with Type 2 Diabetes in the Detection of Ischemia in Asymptomatic Diabetics
(DIAD) Study. Diabetes Care 2007;30:2892-2898.
Shaw LJ, Berman DS, Maron DJ, Mancini J, Hayes SW, Hartigan PM, Weintraub WS, O’Rourke RA,
Dada M, Spertus JA, Chaitman BR, Friedman J, Slomka P, Heller GV, Germano G, Gosselin G,
Berger P, Kostuk WJ, Schwartz RG, Knudtson M, Veledar E, Bates ER, McCallister B, Teo KK,
Boden WE. Optimal Medical Therapy With or Without Percutaneous Coronary Intervention to
Reduce Ischemic Burden (COURAGE). Circulation 2008;117:1283-1291.
Ahlberg AW, Baghdasarian SB, Athar H, Thompsen JP, Katten DM, Noble GL, Mamkin I, Shah AR,
Leka IA, Heller GV. Symptom-limited exercise combined with dipyridamole stress: Prognostic
value in assessment of known or suspected coronary artery disease by use of gated SPECT
Imaging. J Nucl Cardiol 2008;15:42-56.
Heller GV, Katanick SL, Sloper T, Garcia M. Accreditation for Cardiovascular Imaging. JACC:
Cardio Imaging 2008;1:390-7.
Lertsburapa K, Ahlberg AW, Bateman TM, Katten D, Volker L, Cullom SJ, Heller GV.
Independent and incremental prognostic value of left ventricular ejection fraction determined by
stress gated rubidium 82 PET imaging in patients with known or suspected coronary artery
disease. J Nucl Cardiol 2008 in press
Venero CV, Heller GV, Bateman TM, McGhie AI, Ahlberg AW, Katten D, Courter S, Golub RJ,
Case JA, Cullom SJ. Manuscript under review 2008
Bateman TM, Heller GV, McGhie AI, Courter SA, Golub RJ, Case JA, Cullom SJ. Multicenter
Investigation Comparing a Highly Efficient Half-Time Stress-Only Attenuation Correction Approach
(Astonish) Against Standard Rest-Stress Tc-99m SPECT Imaging. 2008 Under revision.
Noble GL, Ahlberg AW, Kokkirala AR, Cullom SJ, Bateman TM, Cyr GM, Katten DM, Tadeo GD,
Case JA, O’Sullivan DM, Heller GV. Validation of attenuation correction using transmission
truncation compensation with a small field of view dedicated cardiac SPECT camera system. 2008
Mieres JH, Shaw LJ, Hendel RC, Heller GV. The WOMEN Study: What is the Optimal Method
for Ischemia Evaluation in WomeN? 2008 J Nucl Cardiol. In press.
Baghdasarian SB, Heller GV. Patient preparation for nuclear imaging: When should anti-
ischemic medications be withheld? J Nucl Cardiol 2007;14:775-81
Lertsburapa K, Heller GV. Infarct Sizing. 4th edition: Nuclear Cardiac Imaging: Principles and
Applications. Editors: AE Iskandrian, Garcia EV 2008.
Heller GV, Mann A, Hendel RC eds. Nuclear Cardiology: Technical Applications. McGraw-Hill
Polk DM, Watson K. Hospital Discharge after an Acute Event: Evidence for a Systems Approach
to Prevention. Coronary Artery Disease 2006;17(3):239-241.
Kang K, Shaw LJ, Hayes SW, Hackamovitch R, Abidov A, Cohen I, Friedman JD, Thomson LE,
Polk D, Germano G, Berman DS. Impact of body mass index on cardiac mortality in patients
with known or suspected coronary artery disease undergoing myocardial perfusion single-photon
emission computed tomography. J Am Coll Cardiol 2006:47:1418-26.
Wong ND, Gransar H, Shaw LJ, Polk D, Berman DS. Comparison of Atherosclerotic Calcification
Burden in Persons with the Cardiometabolic Syndrome and Diabetes. JCMS 2006;1:90-94.
Paul-Labrador M, Polk D, Dwyer JH, Velasquez I, Nidich S, Rainforth M, Schneider R, Bairey Merz
CN. Effects of a Randomized Controlled Trial of Transcendental Meditation on Components of the
Metabolic Syndrome in Subjects with Coronary Heart Disease. Arch Intern Med 2006;166:1218-
Shaw LJ, Polk D, Merz CN. Assessing mature technology: what is the effect of high-quality risk
stratification evidence with exercise echocardiography and single-photon emission computed
tomography imaging? JACC. 2007;49(2):238-9.
Berman DS, Shaw LJ, Hachamovitch R, Friedman JD, Polk DM, Hayes SW, Thompson LE,
Germano G, Wong ND, Kang X, Rozanski A. Comparative use of radionuclide stress testing,
coronary artery calcium scanning, and noninvasive coronary angiography for diagnostic and
prognostic cardiac assessment. Seminars in Nuclear Medicine. 2007 37(1):2-16.
Rozanski A, Gransar H, Wong ND, Shaw LJ, Miranda-Peats R, Polk D, Hayes SW, Friedman JD,
Berman DS. Clinical Outcomes After Both Coronary Calcium Scanning and Exercise Myocardial
Perfusion Scintigraphy. JACC. 2007;49:1352-1361.
Polk D, Shah PK. Cholesterol ester transfer protein (CETP) and atherosclerosis. Drug Discovery
Today: Therapeutic Strategies. 2007;4:137-145.
White CM, Sander S, Coleman CI, Galagher R, Humphrey C, Henyan N, Gillespie EL, Kluger J.
The Impact of epicardial anterior Fat Pad Retention on Post-Cardiothoracic Surgery Atrial
Fibrillation incidence: The Atrial Fibrillation Supression Trial III (AFIST III). Submitted, Journal of
the American College of Cardiology. 2007. 49(3):298-303.
Baker W, White M, Kluger J, Denowtiz A, Konecny C, Coleman C. Effect of perioperative
corticosteroid use on the incidence of postcardiothoracic surgery atrial fibrillation length of stay.
Heart Rhythm 2007 4(4): 461-468.
Clyne CA, Shah A, Yarlagadda R, Migeed M, Kluger J. Catheter ablation for atrial fibrillation:
Hartford Hospital experience. Conn Med. 2007 71(2): 69-67
Dale KM, Coleman CI Shah SA, Patel AA, Kluger J, White CM. Impact ` of gender on statin
efficacy. Curr Med Res Opin. 2007 23(3): 565-74
White CM, Kluger J, Lertsburapa K, Faheem O, Coleman CI. Effect of preoperative angiotensin
converting enzyme inhibitor or angiotensin receptor blocker use on the frequency of atrial fibrillation
after cardiac surgery: a cohort study from the atrial fibrillation suppression trials II and III. Eur J
Cardiothorac Surg. 2007. 31(5): 818-21
Shah SA, Sander S, Cios D, Lipeika J, Kluger J, White CM. Electrocardiographic and
hemodynamic effects of coenzyme Q10 in healthy individuals: a double-blind, randomized
controlled trial. Ann pharmacother. 2007. 41(3): 420-5
Coleman CI, Makanji S, Kluger J, White CM. Effect of angiotensin-converting enzyme inhibitors
or angiotensin receptor blockers on the frequency of post-cardiothoracic surgery atrial fibrillation.
Ann Pharmacother. 2007. 41(3) 433-7
Patel AA, Clyne CA, Henyan NN, Whiter CM, Zembrowski BF, Migeed M, Yarlagadda R, Kluger
J, Coleman CI. The use of protamine after radiofrequency catheter ablation: A pilot study. J Interv
Card Electrophysiol. 2007.
Dale KM, Lertsburapa K, Kluger J, White CM. Moxifloxacin and torsade de pointes. Ann
Pharmacother, 2007. 41(2):336-40
White CM, Sander S, Coleman CI, Gallagher R, Takata H, Humphrey C, Henyan N, Gillespie EL,
Kluger J. Impact of epicardial anterior fat pad retention on postcardiothoracic surgery artial
fibrillation incidence: the AFIST –III Study. J Am Coll Cardiol. 2007. 49(3):298-303
Coleman CI, Rigali VT, Hammond J, Kluger J, White CM. Evaluating the Safety Implications of
Aprotinin Use: The Retrospective Evaluation of Aprotinin in CardioThoracic Surgery (REACTS).
148. Michael Gold, MD, PhD, FHRS, Jesus Val-Mejias, MD, Robert B. Leman, MD,
Rangarao Tummala, MD, Sanjeev Goyal, MD, Jeffrey Kluger, MD, Mark Kroll, PhD, FHRS,
Ashish Oza, MS. Optimization of superior vena cava coil position and usage for transvenous
defibrillation. Heart Rhythm, March 2008. 5(3): 394-399
Brian F. McBride, PharmD, C. Michael white, PharmD, FCCP, FCP, James S, Kalus, PharmD,
BCPS, Danette C. Guertin, MSN, APRN, Christopher A. Clyne , MD, William L. Baker, PharmD,
BCPS, and Jeffrey Kluger, MD, FACC. The impact of carvedilol in the defibrillation threshold.
Heart & Lung Vol. 37, No. 1 Feb, 2008
Gualberto Ruaño, James Bernene, Andreas Windemuth, Bruce Bower, Detlef Wencker, Richard
L. Seip, Mohan Kocherla, Theodore R. Holford, William Petit, Stephen Hanks. (2008)
Physiogenomic Comparison of Edema and BMI in Patients Receiving Rosiglitazone or Pioglitazone
(Journal of Cardiac Failure, submitted)
Detlef Wencker, Acute Cardio-Renal Syndrome: (2007) Progression from Congestive Heart
Failure to Congestive Kidney Failure, Current Heart Failure Reports. 4(3), 134-138
Detlef Wencker, Joseph Feldschuh, Stuart D Katz. (2007) Optimization of Volume Status and
Arterial Perfusion Pressure in Chronic Heart Failure: A Rational Approach Based on Direct Blood
Volume Measurement. (European Journal of Heart Failure, submitted)
Luisa F Durango, Stuart D Katz, Hung-Kei Li, Detlef Wencker. (2008) Continuous Furosemide
Infusion is Safe and Effective in Outpatient Treatment of Refractory Heart Failure. (Circulation, in
Luisa F Durango, Stuart D Katz, Hung-Kei Li, Detlef Wencker. (2006) Outpatient Treatment of
Refractory Heart Failure with Intravenous Furosemide Infusion. J Cardiac Failure 6: S115.
Dewland T, Wencker D, Androne AS, Hrniewiczk K, Katz SD. (2006) Clinical Correlates of Post-
Exercise Heart Rate Recovery in Chronic Heart Failure. Journal of Cardiac Failure 6: S13
Carlos Mena, MD, Detlef Wencker, MD, Harlan M. Krumholz, MD, SM, Robert L. McNamara, MD.
(2006). Detection Of Heart Transplant Rejection In Adults By Echocardiographic Diastolic Indices:
A Quality Review Of The Literature, J Am Soc Echocardiogr. 2006 Oct;19(10):1295-300. Review
Clyne CA, Athar H, Shah A, Kahr R, Rentas A. Thermal Mapping of Right Ventricular Outflow
Tract Tachycardia. PACE, 2007 , March; 30(3): 343-51.
Kapetanopolous A, Peckham G, Kiernan F, Clyne CA, Kluger J, Migeed M, Implantation of a
biventricular pacing and defibrillator device via a persistant left superior vena cava. J Cardiovasc
Med (Hagerstown). 2006 Jun;7(6):430-3
Clyne CA, Shah A, Yarlagadda R, Migeed M, Kluger J. Catheter Ablation for Atrial Fibrillation:
Hartford Hospital Experience. Connecticut Medicine, 2007, February; 1 (2): 69-76.
Patel A, Clyne CA, Henyan N, White M, Zembrowski B, Migeed M, Yarlagadda R, Kluger J,
Coleman C. The use of protamine after radiofrequency catheter ablation: A pilot study. J Interv.
Card. Electrophysiol. 2007, February ; 18(2):155-158.
Patel AA, Clyne CA, Henyan NN, White CM, Zembrosky B, Migeed M, Yarlagadda R, Kluger J,
Coleman CI. The Impact of Protamine on Thrombotic and Bleeding Complications in Patients
Finishing Radiofrequency Catheter Ablation. Journal of Interventional Electrophysiology 2007:
Guertin D, Faheem O, Ling T, Pelletier G, McComas D, Yarlagadda R, Clyne C, Kluger J.
Electromagnetic Interference (EMI) and arrhythmic events in ICD patients undergoing
gastrointestinal procedures. Pacing Clin Electrophysiol. 2007, June; 30(6):734-9.
McBride BF, White CM, Kalus J, Guertin D, Clyne C, Baker W, Kluger J. The Impact of Carvedilol
on the Defibrillation Threshold. Heart & Lung 2008;37:67-71.
Coleman C, Kluger J, Bhavnani S, Clyne C, Yarlagadda R, Guertin D, White M. Association
between statin use and mortality in patients with implantable cardioverter-defibrillators and left
ventricular systolic dysfunction. Heart Rhythm. 2008, April 5(4) 507-510.
Shah S, Clyne CA, Henyan N, Migeed M, Yarlagadda R, Silver B, Kluger J, White CM. The Impact
of Magnesium Sulfate on Serum and Intracellular Magnesium Concentration Amongst Patients
Undergoing Radio Frequency Catheter Ablation.
Connecticut Medicine, May, 2008.